Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism

NCT06293950 is registered in ClinicalTrials.gov with University of Jordan as lead sponsor.

NCT NCT06293950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06293950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Allogeneic Wharton Jelly Mesenchymal Stromal Cell (WJMSC) for Treatment of Autism
Lead sponsor
University of Jordan
Phase
Phase 1
Overall status
Recruiting
Start date
March 9, 2022
Completion date
December 31, 2027
Enrollment
14 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autism